Related Experiment Video
Updated: Jan 10, 2026
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non-Small Cell Lung Carcinomas
Cristiana M Pineda1, Zoe Guan2, Hyunwoo Kwon3
1Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Summary
STK11 mutations in non-small cell lung cancer (NSCLC) drive aggressive tumor growth and immune evasion. Specific STK11 subtypes impact metastasis, particularly to the brain, and reduce survival, guiding future lung cancer treatment.
Area of Science:
- Oncology
- Genomics
- Immunopathology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
- STK11 (LKB1) mutations occur in 20% of NSCLCs, impacting metabolism, polarity, and stress responses, leading to immune evasion and therapy resistance.
- The clinicopathological significance of diverse STK11 mutation subtypes is not fully understood.
Purpose of the Study:
- To investigate the clinicopathological significance of STK11 mutation subtypes in NSCLC.
- To correlate STK11 mutations with tumor histology, behavior, metastatic potential, and clinical outcomes.
Main Methods:
- Retrospective analysis of a large NSCLC cohort (STK11-mutant and wild-type).
- Utilized next-generation sequencing, immunologic biomarkers, histopathological characterization, and radiographic imaging.
Main Results:
- STK11-mutant NSCLCs exhibit heterogeneous molecular and morphologic features.
- These tumors show aggressive growth patterns, lymphovascular invasion, and spread through airspaces.
- Stage 4 STK11-mutant NSCLCs have distinct organotropism, with STK11-loss associated with high rates of brain metastases.
- All STK11 mutations decreased overall survival, most significantly in the STK11-loss/KRAS-mutant group.
Conclusions:
- STK11-mutant NSCLCs are heterogeneous, impacting prognosis and therapeutic response.
- Understanding specific STK11 mutation subtypes is crucial for personalized lung cancer treatment and prognosis.
